UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

UCB United Kingdom United States of America Germany Spain Belgium Austria Italy Netherlands Switzerland Portugal New Jersey

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsiesData include an open-label extension study describing the long-term safety of FINTEPLA®? (fenfluramine)[1] and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome[2]Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the daily impacts of unpredictable seizures and disruptive behaviors[3],[4]Additional focus on defining prolonged seizures and their real-world impact on patients and caregivers[5],[6],[7]View original content:https://www.prnewswire.co.uk/news-releases/ucb-presents-latest-research-and-clinical-advancement-across-leading-epilepsy-portfolio-at-international-epilepsy-congress-302541780.html